Correction: Targeting PARP-1 with metronomic therapy modulates MDSC suppressive function and enhances anti-PD-1- immunotherapy in colon cancer

• Mark Awad,
• Mizuki Nishino,
• Mariano Severgnini,
• Biagio Ricciuti,
• Joao V Alessi,
• Gonzalo Recondo,
• Marissa Lawrence,
• Greg Jones,
• Tim Forshew,
• Christine Lydon,
• Michael Cheng

Affiliations

Mark Awad

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Mizuki Nishino

Radiology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Mariano Severgnini

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Biagio Ricciuti

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Joao V Alessi

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Gonzalo Recondo

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Marissa Lawrence

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Greg Jones

Inivata, Research Triangle Park, North Carolina, USA

Tim Forshew

Inivata, Research Triangle Park, North Carolina, USA

Christine Lydon

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA

Michael Cheng

Medical Oncology, Lowe Center for Thoracic Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA